OncoMatch/Clinical Trials/NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Is NCT04836507 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including CRC01 and Fludarabine for relapsed large b-cell lymphoma.
Treatment: CRC01 · Fludarabine · Cyclophosphamide — This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: rituximab
Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab, anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT.
Must have received: anthracycline
Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab, anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT.
Cannot have received: anti-CD19/anti-CD3 therapy
Prior treatment with any prior anti-CD19/anti-CD3 therapy or any other anti-CD19 therapy
Cannot have received: adoptive T cell therapy
Prior treatment with any adoptive T cell therapy
Cannot have received: gene therapy product
Treatment with any prior gene therapy product
Cannot have received: allogeneic HSCT
Prior allogeneic HSCT
Lab requirements
Blood counts
Hemoglobin > 8.0g/dL; ANC > 1,000/μL; ALC ≥ 300/μL; Platelets ≥ 50,000/μL (without transfusions within 2 weeks prior to screening)
Kidney function
Serum creatinine ≤ 1.5 X ULN; eGFR ≥ 60mL/min/1.73m2
Liver function
Total Bilirubin ≤ 2.0mg/dL (Gilbert-Meulengracht syndrome: ≤ 3 X ULN and direct bilirubin ≤ 1.5 X ULN); AST and ALT ≤ 3 X ULN (≤ 5 X ULN with liver metastasis)
Cardiac function
Hemodynamically stable, without pericardial effusion and LVEF ≥ 50% confirmed by Echocardiogram (ECG) or MUGA
Adequate renal and hepatic functions based on the laboratory test results; Adequate hematologic function without transfusions within 2 weeks prior to screening; Hemodynamically stable, without pericardial effusion and LVEF ≥ 50% confirmed by Echocardiogram (ECG) or Multigated Radionuclide Angiography (MUGA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04836507 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD19/anti-CD3 therapy, adoptive T cell therapy, gene therapy product disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify